Enovis (NYSE:ENOV) Releases Earnings Results

Enovis (NYSE:ENOV) posted its quarterly earnings results on Thursday. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14, FiscalAI reports. Enovis had a negative net margin of 52.69% and a positive return on equity of 7.91%. The business had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same period in the prior year, the business posted $0.98 earnings per share. Enovis’s revenue for the quarter was up 2.6% compared to the same quarter last year. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis’ conference call:

• The company delivered solid full-year results with 6% organic revenue growth (Recon +8%, PNR +4%), maintained ~18% adjusted EBITDA margins, returned to positive free cash flow of $20M, and guided 2026 revenue of $2.31B–$2.37B with mid-single-digit organic growth and a targeted 25%+ free cash flow conversion for the year.
• Management recorded a $501 million non-cash goodwill impairment in Q4, which it says does not affect liquidity, cash flows, or debt covenants but highlights valuation pressures on the business.
• Innovation and product momentum accelerated—the company saw 50% more 510(k) clearances than its prior best year, is launching ARVIS with flexible commercial models at AAOS, and reported strong early adoption for Nebula and OrthoDrive alongside double-digit extremities and international Recon growth.
• Near-term headwinds remain from about $15M of tariffs and calendar effects (Q4 had four fewer selling days, a ~400bp organic-growth headwind; Q1 2026 also has two fewer days and a high comparable), which constrained quarterly performance and margin flow-through.

Enovis Price Performance

NYSE ENOV opened at $25.49 on Friday. The stock has a 50-day simple moving average of $24.27 and a 200 day simple moving average of $28.19. Enovis has a twelve month low of $21.00 and a twelve month high of $40.69. The stock has a market capitalization of $1.46 billion, a PE ratio of -1.23 and a beta of 1.52. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22.

Insider Buying and Selling

In other news, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Enovis

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC lifted its position in Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after buying an additional 73,116 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares in the last quarter. Finally, Amundi increased its stake in Enovis by 24,405.0% in the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after acquiring an additional 9,762 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. BTIG Research upped their target price on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday. Evercore restated an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Wells Fargo & Company raised their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. UBS Group reissued a “buy” rating and issued a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Finally, Canaccord Genuity Group cut their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $47.43.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Adjusted EPS beat — Enovis reported adjusted EPS $0.95 versus consensus ~$0.81, signaling underlying profitability on a non‑GAAP basis. Enovis Q4 2025 Earnings Call Highlights
• Positive Sentiment: Management raised FY2026 adjusted EPS guidance to $3.52–$3.73 (above consensus ~3.35) and expects adjusted EBITDA expansion, providing a clearer path to earnings recovery. Enovis targets $2.31–$2.37B 2026 revenue
• Positive Sentiment: Operational momentum — full‑year 2025 net sales grew ~7% (6% organic) with Reconstructive up ~10% Y/Y; adjusted EBITDA and adjusted EPS for the year improved on a non‑GAAP basis. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst activity supportive — BTIG raised its price target to $43 and keeps a buy stance, signaling some sell‑side confidence in the recovery story. BTIG price target raise
• Neutral Sentiment: Guidance mix — revenue guidance of $2.31–$2.37B implies 4–6% organic growth (positive), but the top‑end sits below some street expectations — a watch item for revenue‑sensitive investors. Guidance detail
• Negative Sentiment: Revenue miss and GAAP impairment — Q4 revenue ~$575.8M missed consensus (~$584M) and the company took a $501M non‑cash goodwill impairment (Q4) that produced a large GAAP loss (Q4 net loss from continuing operations ~$519M), raising concerns about past acquisition valuation and near‑term GAAP volatility. Enovis Misses Q4 Sales Expectations
• Negative Sentiment: Significant non‑cash charges dent headline results — investors focused on GAAP losses and goodwill write‑downs may remain cautious despite positive adjusted metrics. Quiver/summary of results and impairment

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.